HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma
T he fibroblast growth factor receptor (FGFR) family consists of four members (FGFR1-4) that are activated by a number of ligands belonging to the FGF family. Ligand binding to the extracellular domain induces FGFR dimerization, which in turn causes allosteric activation of the receptor tyrosine kinase domain (TKD) and initiation of downstream signaling. (1) This tightly regulated process may be rendered constitutive by FGFR1-4 point mutations that are observed recurrently in several cancer types and believed to be involved in tumor pathogenesis.
(1) FGFR1-3 oncogenic conversion may also be caused by chromosomal translocations that generate FGFR-containing fusion proteins in several human tumors.
(2) Herein, we focus on FGFR2 fusion proteins (henceforth referred to as FFs) that are recurrently detected in intrahepatic cholangiocarcinoma (ICC) . (3) The ICC FFs contain residues 1-768 of the FGFR2IIIb isoform fused C-terminally to any of a growing list of fusion partners (about 20 identified so far). Sequences contributed by FF fusion partners are thought to cause constitutive dimerization and catalytic activation of the FGFR2 TKD, which in turn ignites FF oncogenic activity. (2) ICC is a deadly tumor whose global incidence is steadily increasing. Although surgery may attain a cure in a fraction of cases, the 5-year survival rate for inoperable patients is a dismal 5%-10%. Recently, integrated high-content screenings have provided a compendium of ICC genomic vulnerabilities, therefore creating unprecedented opportunities for precision medicine approaches to this severe tumor. (3) In this framework, FGFR2 fusion proteins have drawn a great deal of attention because (1) their prevalence in ICC is a notable 10%-15% (3) (4) (5) (6) (7) ; (2) FF-expressing ICCs are grouped within a molecularly distinct subtype of ICC (6) ; and (3) FFs are considered ICC oncogenic drivers, a notion based on the observation that their targeting by FGFR tyrosine kinase inhibitors (F-TKIs) may yield objective clinical responses. (3) This has provided the rationale for a phase II clinical trial, designed to test the efficacy of the F-TKI BGJ398 in ICC patients selected for the presence of FGFR2 fusions (ClinicalTrials.gov identifier: NCT02150967). Results from this trial have documented meaningful rates of clinical response (18.8%) and disease control (83.3%) in patients with advanced or metastatic ICC who had progressed during therapy. (8) Thus, FF targeting by F-TKIs appears to represent the first significant advancement in the so far disappointing quest for genomics-based therapies in cholangiocarcinoma patients. As a consequence, improving the efficacy of FF therapeutic targeting is a pressing clinical need. (9) The acquisition of a constitutively active conformation causes a degree of structural instability in many oncogenic kinases, including those co-opted in fusion proteins. (10) Consequently, these oncoproteins require assistance by the HSP90 chaperone machinery to maintain their native fold and avoid the degradation fate imposed on misfolded proteins by the proteome quality control (QC) machinery. (10) This notion has provided the rationale underpinning the use of pharmacological inhibitors of HSP90 (HSP90i) for therapeutic targeting of oncogenic kinases. (10) Within this conceptual framework, attention has recently been drawn to combined targeting of oncogenic kinases through HSP90 inhibition and catalytic blockade, a two-hit strategy aimed at integrating the functional inhibition of the target kinase with its proteolytic destruction. (11) Herein, we report that three FFs, previously identified in ICC, are HSP90 clients and as such undergo rapid degradation in cells subjected to HSP90 inhibition. Furthermore, we show that FF targeting by BGJ398 in combination with the clinically advanced HSP90 inhibitor ganetespib (12) elicits superior suppression of FF oncogenic signaling in cultured cells and FF-driven NIH3T3 tumor allografts. Finally, we demonstrate that three distinct FF mutants, recently shown to confer clinical resistance to BGJ398 in ICC patients, (13) retain sensitivity to ganetespib. Our data provide a proof of principle that HSP90 inhibition affords a significant improvement of FF targeting by F-TKIs.
Materials and Methods

Cell CUltUre aND CHemiCalS
NIH3T3 and HEK293 cells were obtained from ATCC, cultured in D-MEM medium (Lonza) containing 10% (vol/vol) fetal bovine serum (Euroclone) and routinely tested for mycoplasma by the N-GARDE PCR detection kit (Euroclone). When required, cells were starved in D-MEM/Ham's F12 (1:1 mixture, artiCle iNFormatioN: Lonza) containing 0.2% serum (referred to in the text as "low serum medium"). Ganetespib and BGJ398 were from MedChem; 17-AAG and AZD4547 were from Selleckchem; endoglycosidase H and PNGase F were purchased from New England Biolabs; and tunicamycin, cycloheximide, MG132 and bafilomycin were from Calbiochem.
immUNoCHemiCal proCeDUreS
Cell lysis, immunoprecipitation (IP), western blotting, and ECL detection protocols were described by Frosi et al. (14) and are reported in detail in the Supporting Information. Antibodies used in western blotting procedures are indicated in the Supporting Information. For IPs, the affinity-purified anti-Myc mAb 9E10 was coupled covalently to Protein G-sepharose (GE Healthcare) and used at 10 micrograms per IP. AntiMyc nanobodies bound to agarose were from Chromo Tek (Planegg-Martinsried, Germany) and used at 10 micrograms per IP. Endo H and PNGase F assays were carried out as suggested by the manufacturer.
Cell imagiNg
For cell imaging studies, cells were processed for staining as described by Frosi et al. (14) Briefly, cell monolayers were rinsed with phosphate-buffered saline (PBS) (+ Ca ++ /Mg ++ ), fixed with 4% paraformaldehyde in PBS for 10 minutes and permeabilized with 0.5% Triton X-100 in PBS at 20°C. For LAMP1 labeling, cells were fixed with methanol at −20°C for 5 minutes. Cells were then incubated with primary antibodies and subsequently with conjugated secondary antibodies (1 hour at room temperature) in 1% radioimmunoassay-grade bovine serum albumin; finally, coverslips were mounted with Gelvatol. Early endosomes were stained with a polyclonal anti-EEA1 antibody (sc-6415, Santa Cruz Biotechnology); late endosomes/lysosomes were stained with a monoclonal anti-Lamp1 antibody (eBio1D4B, Invitrogen-Thermo Fisher). Fluorescein isothiocyanate (FITC)-conjugated and tetramethyl rhodamine isothiocyanate (TRITC)-conjugated antibodies were from Jackson ImmunoResearch. Nuclei were stained by Hoechst 33258 (Molecular Probes, Invitrogen). Samples were examined with a microscope (model AX70; Olympus America Inc.) equipped with a 40×/0.75 PH2 and 60×/1.40 oil objective lenses. Images were recorded on a XM10 CCD camera run by cellSens software (Olympus America Inc.). Confocal images were taken using an Olympus FV1200 microscope (equipped with a 60×/1.40 oil objective) at 1.5 or 2.0 zoom. Colocalizations were recorded using sequential recording with line average. Recorded fluorescent images in OIB format were converted to TIFF images with ImageJ and further processed with Adobe Photoshop software (using linear curve correction for adjusting brightness and contrast to whole images; levels were adjusted equally for all images in a set). 4 NIH3T3 cells expressing F-TACC3 in 0.1 mL PBS. Drug treatments of randomized animal groups were started when tumors reached a 80-100 mm 3 volume, which took about 10-12 days. BGJ398 and ganetespib were purchased from MedChem. BGJ398 was dissolved in 30% PEG-400 (Sigma), 0.5% Tween 80 (Sigma), and 5% polypropylenglycol (Sigma) and dosed at 15 mg/kg daily by oral gavage for 6 days per week. Ganetespib was dissolved in 10% DMSO (Sigma), 18% Kolliphor RH-40 (Sigma), and 3.6% Dextrose (Sigma) and dosed at 100 mg/kg once a week by intravenous injection. Control mice were treated with carrier following the same schedule. When required, mice were anesthetized and euthanized by cervical dislocation.
reCombiNaNt DNa aND geNe traNSFer proCeDUreS
immUNoHiStoCHemiStry aND termiNal DeoXyNUCleotiDyl traNSFeraSe-meDiateD NiCK eND labeliNg aSSay
Tumors explanted from mice were fixed in 4% paraformaldheyde and paraffin-embedded for immunohistochemistry (IHC) analysis. Antibodies were used as detailed in the Supporting Information. For each tumor, three different 5-μm paraffin sections were analyzed and examined by light microscopy. Quantification of TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling), anti-CD31, and anti-Ki-67 reactivity was performed as detailed in the Supporting Information.
StatiStiCal aNalySiS
Values were expressed as average ± SEM. One-way analysis of variance (ANOVA) with a post hoc Dunnett's test was used for multiple sample comparisons. The student's t-test (unpaired, two-tailed) was used for single pair-wise comparisons. Differences were considered statistically significant when P < 0.05.
Results
bioSyNtHetiC proCeSSiNg oF FgFr2 FUSioN proteiNS
Western blot analysis of wt FGFR2IIIb yields a 110-125-KDa doublet. The 110-KDa band corresponds to the endoplasmic reticulum (ER)-located, partially glycosylated primary translational product, which, upon transiting through the Golgi, matures into the 120-125-KDa fully glycosylated receptor destined to the plasmamembrane. (15) Ectopic expression of three structurally different FGFR2 fusions isolated from ICC, namely F-TACC3, F-MGEA5 (meningioma expressed antigen 5), and F-BICC1 (BicC family RNA binding protein 1), (16) also yielded doublets, albeit, as expected, of higher molecular weight (MW) (Supporting Fig. S1A) . Results from Endoglycosidase H and PNGase F digestion assays with each of these FFs indicated that the lower MW band corresponds to the ER-located primary translational product, whereas the higher MW band corresponds to the mature form. As expected, PNGase F digestion in vitro yielded a band whose MW was similar to that of the sugar-free polypeptide core expressed in tunicamycin-treated cells (Supporting Fig. S1A ). Anti-phospho-FGFR (pFGFR) immunoblots yielded a single band corresponding to the higher MW isoform of FFs (Fig. 1B-D) . (2) We conclude that FFs undergo canonical biosynthetic processing through the ER and Golgi compartments and become catalytically active upon the acquisition of their mature glycosylation pattern.
FgFr2 FUSioN proteiNS are HSp90 ClieNt proteiNS
Because most oncogenic fusion proteins require assistance by the HSP90 chaperone machinery to acquire/ maintain their correct folding, (10) we considered the possibility that FFs are HSP90 clients. Anti-FF immunoprecipitants subjected to western blot analysis with anti-HSP90 antibodies revealed that F-TACC3 and F-MGEA5 were constitutively bound to HSP90. This molecular complex underwent rapid dissociation in cells treated with two structurally different HSP90 inhibitors, namely 17-AAG and ganetespib (17) ( Fig. 1A and Supporting Fig. S1B ). Physical association of FFs with HSP90 appears to be functionally relevant because the expression of F-TACC3, F-MGEA5, and F-BICC1 was suppressed in cells exposed to either ganetespib or 17-AAG, the most prominent effect being on the mature form of FFs (see subsequently for further discussion). This effect was dose-dependent (Fig. 1B,C and Supporting Fig. S2A,B) , with ganetespib being active against FFs in the nanomolar range (Fig. 1B,C) . The latter finding compared favorably with ganetespib activity against EML4-ALK (Supporting Fig. S2C ), a bona fide HSP90 client. (18) In contrast, high doses of 17-AAG remained ineffective against wt FGFR2 (Supporting Fig. S2D ), as reported by Laederich et al. (19) A sizeable reduction of F-T expression could be documented within 1-2 hours of HSP90 inhibition (Fig. 1D) , a datum consistent with HSP90i leading to accelerated FF degradation.
This was formally proved in cycloheximide (CHX)-chase experiments, which indicated that the stability of FFs was dramatically compromised by HSP90 inhibition ( Fig. 2A) . CHX experiments also indicated that beside the mature, fully glycosylated form, also the ER-resident form of both F-TACC3 and F-MGEA5 underwent swift degradation following HSP90 inhibition ( Fig. 2A) . Likely, in experiments performed in absence of CHX, the vigorous rate of synthesis of ectopically expressed FFs partially compensates for the depletion of ER-located FFs caused by HSP90i, thus masking the effects of HSP90i on the pool of nascent FFs. In aggregate, these experiments substantiate the notion that FFs are HSP90 clients.
HSP90 client proteins that undergo unresolved misfolding, either spontaneously or following pharmacological HSP90 inhibition, are tagged for degradation through ubiquitin conjugation. In line, F-TACC3 and F-MGEA5 were ubiquitylated at steady state. Interestingly, F-MGEA5 showed a higher stoichiometry of ubiquitylation when compared with F-TACC3 ( Fig. 2B and Supporting Fig. S2E ), which was concordant with F-MGEA5 being expressed at lower levels than F-TACC3 in both HEK293 and NIH3T3 cells (Supporting Fig. S2F ). We consistently observed increased ubiquitylation of F-TACC3 following HSP90 inhibition, which was instead uncommon in the case of F-MGEA5 (Fig. 2B and Supporting Fig.  S2E ). We suspect that major factors affecting our ability to detect a clear-cut increase of F-MGEA5 ubiquitylation following HSP90 inhibition were high basal ubiquitylation of F-MGEA5 and low recovery in anti-Myc IPs of the poorly expressed post-Golgi F-MGEA5 pool ( Fig. 2B and Supporting Fig. S2E ), which, in fact, is the main target of HSP90i-driven degradation ( Fig. 2A) .
proteolytiC roUteS oF FgFr2 FUSioN proteiNS
Lysosomes and the proteasome are subcellular organelles specialized in protein degradation. Blocking protein degradation in the lysosome by the vacuolar-type H + -ATPase inhibitor bafilomycin A1 and in the proteasome by MG132 caused a sizeable accumulation of F-TACC3 at steady state and rescued F-TACC3 from ganetespib-induced degradation (Fig. 2C, left) . Similar results were obtained with F-MGEA5. The . Controls included cells expressing only HA-Ub. Cells were treated with either vehicle or ganetespib (0.5 μM) for 30 minutes at 37°C and lysates were subjected to anti-Myc IP followed by western blot analysis with indicated antibodies (see also Supporting Fig. S2E ). (C) NIH3T3 cells expressing Myc-tagged FFs were incubated for 3 hours in low serum medium with cycloheximide (100 μg/ml), bafilomycin A1 (50 nM), MG132 (10 μM), or ganetespib (80 nM), either alone or in the indicated combinations. Cell lysates were immunoblotted with the indicated antibodies. (D) NIH3T3 cells expressing Myctagged FFs were incubated for 3 hours in low serum medium with cycloheximide (100 μg/ml), AZD4547 (100 nM), or bafilomycin A1 (50 nM) as indicated. Lysates were immunoblotted with the indicated antibodies.
latter experiment was carried out in the presence of CHX, which allowed a better capture of FF dynamics following experimental perturbations (Fig. 2C, right) .
In MG132-treated cells, accumulation of the ER-located form of both F-MGEA5 and F-TACC3 (Fig. 2C) reflected most likely the delivery to the proteasome of misfolded neo-synthesized FFs, (20) consistent with immature FFs being HSP90 clients (Fig. 2A) . The minor accumulation of ER-resident FFs in bafilomycin-treated cells was most likely caused by bafilomycin-induced inhibition of ER to Golgi traffic. (21) Overall, it was the mature form of FFs that accumulated to the highest degree following either bafilomycin or MG132 treatment, in both control and ganetespib-treated cells (Fig. 2C) . Although it has been shown that proteasome inhibition may attenuate degradation of some receptor tyrosine kinases (RTKs), (22, 23) it is unclear whether this is due to a direct or indirect effect. However, it is well established that activated RTKs, including FGFR2, undergo activity-dependent endocytosis, which may culminate in ubiquitin-dependent sorting into late endosomes/ lysosomes, RTK degradation, and eventual attenuation of receptor signaling. (24) Ubiquitylation-dependent endocytosis and degradation in the lysosome compartment have also been implicated in proteolytic disposal of misfolded cell surface proteins, including HSP90 clients, by the QC machinery. (25) We observed that FFs, despite showing at steady state a prevalent, if not exclusive, localization in intracellular compartments, (26) accumulated at the cell periphery following treatment with the F-TKI AZD4547 (Fig. 3A) . This peripheral compartment corresponded to the plasmamembrane, because in nonpermeabilized cells FFs were bound by two different antibodies against the FGFR2 extracellular domain (Fig. 3B,C) . This suggests that FFs undergo activity-dependent endocytosis after reaching the plasmamembrane. Unlike bafilomycin, AZD4547 did not lead to F-TACC3 accumulation and was inferior to bafilomycin in rescuing F-MGEA5 expression (Fig. 2D ). This implies that activity-dependent endocytosis of FFs may be uncoupled from downregulation, at variance with the scenario described for wt FGFR2. (27) We therefore surmised that bafilomycin sensitivity of post-Golgi FFs (Fig. 2C,D) could reflect the QC-dependent disposal into lysosomes of misfolded FFs that failed to undergo HSP90-assisted refolding, whether at steady state or upon HSP90 inhibition. In line with this hypothesis, F-MGEA5 was imaged in late endosomes/lysosomes, with this immuno-detection being increased by ganetespib treatment despite concurrent F-MGEA5 inhibition by AZD4547 (Supporting Fig. S3A) . Moreover, the pool of kinase-inhibited F-MGEA5 and F-TACC3 located at the plasmamembrane was cleared from the cell surface following ganetespib treatment (Fig. 3B) , in what appeared to be an endocytosis-dependent/activityindependent process leading to FF colocalization with the early endosome marker EEA1 (Fig. 3C) . Finally, and in agreement with the prediction that the QC machinery targets misfolded FFs regardless of their activation state, AZD4547 did not inhibit degradation of post-Golgi F-MGEA5 in ganetespib-treated cells (Supporting Fig. S3B) .
In summary, these data are compatible with a minimal model in which post-Golgi FFs undergo rapid endocytosis after reaching the plasmamembrane. In the case of FFs maintaining their native fold, this endocytic route requires kinase activity and likely causes FFs to recycle back to the plasmamembrane (except for a fraction of native F-MGEA5 that is diverted to lysosomes). Post-Golgi FFs that experience unresolved misfolding appear to be sorted to lysosomes, a process that 1) is driven by the QC machinery; 2) does not require FF kinase activity; 3) is responsible for FF proteolytic disposal also in ganetespib-treated cells. Similar to the established scenarios of QC operating on misfolded HSP90 clients located at the plasmamembrane, (25) this model predicts that endocytic sorting to lysosomes is driven by FF ubiquitylation. As discussed previously and in line with this prediction, we observed basal FF ubiquitylation, which was also detectably stimulated by HSP90 inhibition in the case of F-TACC3 (Fig. 2B and Supporting Fig. S2E ).
HSp90 iNHibitioN improVeS tHerapeUtiC targetiNg oF FgFr2 FUSioN proteiNS by F-tKiS
These data show that three different FFs isolated from ICC are vulnerable to HSP90i. We surmised that combining catalytic blockade of FFs with their HSP90i-driven proteolytic destruction could improve therapeutic targeting of FFs.
Prodromic dose-response experiments with two clinically advanced F-TKIs, namely AZD4547 and BGJ398, (1) in cells expressing F-TACC3, F-MGEA5, or F-BICC1 revealed that AZD4547 and BGJ398 suppressed FF oncogenic signaling with IC 50 in the nanomolar range, yielding complete ablation of pFGFR and phospho extracellular signal-regulated kinases (pERKs) immunoreactivity at 100 and 50 nM, respectively (Supporting Fig. S4A-D) . These experiments confirmed that, at variance with post-Golgi F-MGEA5, neither F-TACC3 nor F-BICC1 accumulated in F-TKI-treated cells. Next, we tested whether combining suboptimal doses of F-TKIs (either AZD4547 or BGJ398) with HSP90i (either 17-AAG or ganetespib) could still afford effective suppression of F-TACC3 signaling in cultured cells. Both the BGJ398+ganetespib (B+G) (Fig. 4A ) and AZD4547+17AAG (Supporting Fig. S3C ) combinations yielded superior suppression of F-TACC3 signaling when compared with single drug treatments.
Motivated by these data, we tested the activity of BGJ398 and ganetespib against tumors generated by subcutaneous injection in immuno-compromised mice of F-TACC3 NIH3T3 transformants. We chose F-TACC3 because it yielded a 5-10-fold higher transforming activity in the NIH3T3 focus assay, when compared with both F-BICC1 and F-MGEA5 (data not shown), therefore providing a stringent challenge to our experimental hypothesis. Drug treatments began when tumors reached an average volume of 80-100 mm 3 . Although in untreated mice F-TACC3 tumors grew vigorously, reaching within 10 days an average volume of 2500 mm 3 , which was incompatible with further animal survival, BGJ398 and ganetespib suppressed tumor growth at day 10 to an average value of 17% and 31%, respectively. The B+G treatment yielded a virtually complete suppression of tumor growth at the same endpoint (Fig. 4B) . Statistical analysis by one-way ANOVA indicated that the observed differences were significant (P < 0.001). Beyond day 10, single drug treatments lost efficacy. In contrast, the B+G combo allowed protracted suppression of tumor growth, which, in comparison with single agent BGJ398, remained statistically significant also at day 14 (P < 0.001 by student's t-test). Drug treatments were well tolerated, as determined by visual assessment of parameters linked to animal well-being (coat conditions, posture, lameness, and food/water consumption) and body weight monitoring (Supporting Fig. S5A ). IHC analyses confirmed that individual treatments led to inhibition of F-TACC3 catalytic activity and downstream oncogenic signaling, as assessed by anti-pFGFR and anti-pERKs immunostaining. Remarkably, the B+G combo elicited the strongest inhibition (Fig. 4C) . Although the combo treatment did not provide a significant advantage over individual drugs in terms of suppression of angiogenesis and cell proliferation, it was significantly more effective (as assessed by the oneway ANOVA test) in inducing apoptotic cell death ( Fig. 4D and Supporting Fig. S5B ). This suggests that enhanced cell killing was likely to mediate the superior tumor growth control afforded by the B+G combo.
bgJ398 reSiStaNt mUtaNtS oF FgFr2-taCC3 maiNtaiN SeNSitiVity to gaNeteSpib
A major mechanism of clinical resistance to BGJ398 in ICC is the therapy-induced selection of tumor subclones that are driven by TKD-mutated FFs with markedly reduced affinity for BGJ398. (13) We inserted three of these resistance mutations, namely the "gatekeeper" mutation V564F and the "molecular brake" mutations N549H and E565A, (13, 28) in the F-TACC3 background. Notably, we found that all of these mutations retained sensitivity to ganetespib, in fact showing an IC 50 lower than that of wt F-TACC3 (Fig. 4E ). Because these mutations cause a gain of basal FGFR2 (F-T) were incubated in low serum medium for 2 hours with CHX (100 μg/mL) and AZD4547 (100 nM). Permeabilized cells were imaged with anti-Myc tag monoclonal antibody 9E10. The nuclei in some TKI-treated cells appear enlarged, probably as a consequence of nuclear flattening secondary to increased cell spreading. (B) NIH3T3 cells expressing either F-MGEA5 or F-TACC3 were incubated for 2 hours in low serum medium, containing AZD4547 (TKI, 100 nM) and ganetespib (80 nM) as indicated. Cells were fixed with 4% paraformaldehyde and stained without cell permeabilization with the anti-FGFR2 antibody sc-20735, directed against the FGFR2IIIb extracellular domain. The observed immunoreactivity is therefore restricted to FFs exposed at the cell surface. (C) NIH3T3 cells expressing F-MGEA5 were incubated for 2 hours at 37°C in medium containing 100 nM BGJ398, then shifted on ice and incubated for 30 minutes with mAb D4L2V, directed against the FGFR2 extracellular domain. Cells were washed twice on ice before adding a warm medium containing BGJ398 ± ganetespib (80 nM) and chased at 37°C for 30 minutes before being fixed and stained with anti-EEA1 antibody (green). The pool of F-MGEA5 molecules bound by Ab D4L2V (i.e., labeled at the cell surface prior to cell permeabilization) was imaged by a TRITC-conjugated secondary antibody and analyzed by confocal microscopy. Note that F-MGEA5 colocalized extensively with the EEA1 marker in ganetespib-treated cells. However, sparse endocytosis of F-MGEA5 could be imaged also in the absence of ganetespib (top row), supporting a model in which the QC machinery drives activity-independent endocytosis of post-Golgi FFs caught in a state of unresolved misfolding. Nuclei were stained by Hoechst 33258. Scale bars: 20 μm.
kinase activity by altering the TKD conformation, (28) it is possible that they increase the thermodynamic instability of FGFR2 fusions, thus exacerbating their dependence on HSP90.
Discussion
In the present study we demonstrate that three different FFs isolated from ICC are HSP90 clients and show that pharmacological HSP90 inhibition can be leveraged to improve therapeutic targeting of FFs by F-TKIs. Our data are consistent with FFs requiring HSP90 assistance throughout their biosynthetic path and in post-Golgi compartments. Pharmacological inhibition of HSP90 leads to a dramatic acceleration of FF degradation, which we propose to take place in the proteasome in the case of nascent FFs and in lysosomes for post-Golgi FFs; it remains unclear whether the proteasome plays a direct role also in the degradation of a pool of post-Golgi FFs. Because we did not detect significant variations in the sensitivity of three different FFs to HSP90i, it is plausible that dependence on HSP90, and by inference vulnerability to HSP90i, could be a general feature of ICC FFs, thus manifesting itself regardless of the identity of the FGFR2 fusion partner. Generalization of this model awaits that more FFs are tested for their sensitivity to HSP90i in the ICC cell of origin (see subsequently).
We asked whether pharmacological HSP90 inhibition, by virtue of its ability to drive precipitous FF proteolysis, could provide an added therapeutic value to F-TKI-mediated targeting of FFs. The F-TKI plus HSP90i combination outperformed single drugs in suppressing F-TACC3 oncogenic signaling in cultured cells. Likewise, when compared with single drug treatments, the B+G combo afforded superior control of tumor growth in mice transplanted with NIH3T3 cells transformed by F-TACC3. This was associated with a higher rate of cell death in tumors treated with B+G. Although viewing these results as a proof of principle of the F-TKI+HSP90i combo efficacy against FFs, we acknowledge that further experimentation is required for validating this approach in models that recapitulate FF-driven oncogenic signaling in the ICC cell of origin. In this regard, we observed that long-term control of F-TACC3-driven tumor growth required continuous administration of B+G (Supporting Fig.  S5B,C) . It remains to be determined whether and to what extent the B+G combination may exert stronger cytostatic/cytocidal activity in ICC cells addicted to FF signaling when compared with F-TKI monotherapy. Encouragingly, a recent report has hinted that ICC cells are addicted to HSP90 regardless of their mutational landscape. (29) We therefore suggest that the anticancer effects of HSP90 inhibitors in FF-expressing ICCs might integrate suppression of the main oncogenic driver (i.e., FFs themselves), with inhibition of other client/s playing a necessary role in maintaining the ICC transformed phenotype.
In closing, we point to two additional clinical implications of our findings. First, our demonstration that clinically relevant BGJ398-resistant FF mutants maintain full sensitivity to HSP90 inhibition suggests that upfront targeting of FFs with an F-TKI+HSP90i combo could offer the additional advantage of delaying/suppressing secondary resistance to F-TKIs caused by TKD mutations. Moreover, our data that FFs transit through the plasmamembrane imply that FFs can be targeted by anti-FGFR2IIIb therapeutic antibodies. (1) In fact, we suggest that HSP90 inhibition could improve FF targeting by antibody-drug conjugates, as they most often require delivery to lysosomes to release their payload and exert their cytotoxic activity. Future work will explore these hypotheses and likely expand the range of therapeutic options suitable for combating Lysates were immunoblotted to assess F-TACC3 expression, which was quantified as reported in the graph on the right. Statistical significance in (B) and (D) is indicated as follows: *P ≤ 0.05, **P ≤ 0.001, and ***P ≤ 0.0001.
FF oncogenic signaling in ICC and other tumor types in which FFs occur with low prevalence.
